Akums Drugs & Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,024Cr
- +0.5% YoY
- −3% QoQ
- Net profit
- ₹65Cr
- +6.6% YoY
- −56.7% QoQ
- Margin
- 13%
- 0 pp YoY
- +4 pp QoQ
Guidance rank: #25 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
CDMO Business: CDMO Business: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.
From Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO Business:
- Expected mid-single-digit topline growth in FY26 due to continued soft API prices.
- Rs. 300 crore annual revenue anticipated from the new EU CDMO contract starting April 2027, with full ramp-up possibly taking 2-3 years.
- Five-year target of $100 million in exports, scaling up from the current $15 million in formulation exports.
- Domestic Branded Formulations:
- Expected to track IPM growth, with subdued 3-4% growth in Q1 seen as a one-off.
- Anticipated better performance in subsequent quarters, maintaining overall yearly guidance.
- International Branded Formulations:
- High-teen growth expected for the full year despite weaker current quarter.
- API Business:
- Continued focus on global expansion (Europe, Africa, LATAM) and improved API pricing.
- Single-digit growth expected amidst pricing pressure domestically.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
- Current ongoing capex projects include expansion at Baddi plant and utilization ramp-up at Haridwar facility.
- Strategic inorganic investments focus on acquiring dosage form capabilities either within India or abroad to gain access to new markets and expand product portfolios.
- Consideration for acquisitions targeting companies with strong R&D, quality manufacturing, and global market access, aiming to launch new products quickly.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Akums Drugs & Pharmaceuticals has recently received a significant contract worth Rs. 300 crores linked to European markets.
- They have other ongoing contracts of smaller values in progress.
- Current export business run rate stands at Rs. 150 crores.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Akums Drugs & Pharmaceuticals Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,024 | 1,019 | +0.5% | 1,056 | -3% |
| Operating profit (EBITDA) | 129 | 128 | +0.8% | 94 | +37.2% |
| Operating margin | 13% | 13% | 0 pp | 9% | +4 pp |
| Profit before tax | 96 | 87 | +10.3% | 75 | +28% |
| Net profit (PAT) | 65 | 61 | +6.6% | 150 | -56.7% |
| EPS (₹) | 4.03 | 4.08 | -1.2% | 9.38 | -57% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
Earlier calls (2)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q1 FY26 results?
CDMO Business: CDMO Business: Targeting mid-single-digit top-line growth for FY26, a slight moderation due to soft API prices; margins expected around 14-15%.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Jammu plant expansion: Capex to start towards the end of the current year, with completion and plant operational by March 2027.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
